Nemaura Medical Management
Management criteria checks 2/4
Nemaura Medical's CEO is Faz Chowdhury, appointed in Jan 2009, has a tenure of 15.25 years. total yearly compensation is $338.58K, comprised of 29.2% salary and 70.8% bonuses, including company stock and options. directly owns 21.69% of the company’s shares, worth $496.25K. The average tenure of the management team and the board of directors is 3.2 years and 0.2 years respectively.
Key information
Faz Chowdhury
Chief executive officer
US$338.6k
Total compensation
| CEO salary percentage | 29.2% |
| CEO tenure | 15.3yrs |
| CEO ownership | 21.7% |
| Management average tenure | 3.2yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
Nemaura Medical GAAP EPS of -$0.17
Aug 15Nemaura Medical GAAP EPS of -$0.59 misses by $0.12, revenue of $0.51M
Jun 30Nemaura Medical: Opportunity In The Consumer-Centered Continuous Glucose Monitoring Market
Mar 10Nemaura Medical (NASDAQ:NMRD) Has Debt But No Earnings; Should You Worry?
Nov 17
Nemaura Medical: From Believer To Skeptic
Sep 20Nemaura: Wearable Monitoring Patches For Type-2 Diabetics Could Be An Inspired Move
Jul 02Nemaura Medical rallies on 200K sugarBEAT sensors order
May 05Nemaura Medical: Lowering Glucose Levels Will Increase Share Price
Feb 03How Much Of Nemaura Medical Inc. (NASDAQ:NMRD) Do Insiders Own?
Dec 22
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$11m |
| Sep 30 2023 | n/a | n/a | -US$10m |
| Jun 30 2023 | n/a | n/a | -US$13m |
| Mar 31 2023 | US$339k | US$99k | -US$14m |
| Dec 31 2022 | n/a | n/a | -US$13m |
| Sep 30 2022 | n/a | n/a | -US$15m |
| Jun 30 2022 | n/a | n/a | -US$14m |
| Mar 31 2022 | US$113k | US$109k | -US$14m |
| Dec 31 2021 | n/a | n/a | -US$12m |
| Sep 30 2021 | n/a | n/a | -US$10m |
| Jun 30 2021 | n/a | n/a | -US$9m |
| Mar 31 2021 | US$108k | US$105k | -US$6m |
| Dec 31 2020 | n/a | n/a | -US$5m |
| Sep 30 2020 | n/a | n/a | -US$4m |
| Jun 30 2020 | n/a | n/a | -US$4m |
| Mar 31 2020 | US$104k | US$102k | -US$4m |
| Dec 31 2019 | n/a | n/a | -US$4m |
| Sep 30 2019 | n/a | n/a | -US$5m |
| Jun 30 2019 | n/a | n/a | -US$5m |
| Mar 31 2019 | US$105k | US$104k | -US$4m |
| Dec 31 2018 | n/a | n/a | -US$3m |
| Sep 30 2018 | n/a | n/a | -US$3m |
| Jun 30 2018 | n/a | n/a | -US$2m |
| Mar 31 2018 | US$107k | US$106k | -US$2m |
Compensation vs Market: Faz's total compensation ($USD338.58K) is below average for companies of similar size in the US market ($USD668.06K).
Compensation vs Earnings: Faz's compensation has increased whilst the company is unprofitable.
CEO
Faz Chowdhury (50 yo)
15.3yrs
Tenure
US$338,578
Compensation
Dr. Dewan Fazlul Hoque Chowdhury, also known as Faz, Ph. D, founded Nemaura Pharma Limited and also serves as its Chief Executive Officer and Chairman of the Board since 2005. Dr. Chowdhury has been the Ch...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 15.3yrs | US$338.58k | 21.69% $ 496.2k | |
| Chief Operating Officer | 2.3yrs | no data | 0.25% $ 5.7k | |
| Head of U.S. Commercial Operations | 3.2yrs | no data | no data | |
| Head of E.U. Commercial Operations & Marketing | 3.2yrs | no data | no data | |
| Global Head of Digital Programs | 3yrs | no data | no data |
3.2yrs
Average Tenure
Experienced Management: NMRD's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 15.3yrs | US$338.58k | 21.69% $ 496.2k | |
| Advisor of International Growth Opportunities & Member of Executive Advisory Board | 3.1yrs | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Director | less than a year | no data | no data | |
| Director | less than a year | no data | no data |
0.2yrs
Average Tenure
Experienced Board: NMRD's board of directors are not considered experienced ( 0.2 years average tenure), which suggests a new board.